cetuximab
Sign in to saveAlso known as IMC-C225, C225, IMC-225, Anti EGFR
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion.
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 460026782
- Drug.type
- mab
- Drug.image
- Cetuximab.png
- Drug.mab_type
- mab
- Drug.source
- xi/o
- Drug.target
- EGF receptor
- Drug.tradename
- Erbitux
- Drug.DailyMedID
- Cetuximab
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- FE01
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Research
9,866 papers- Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer.Cell death & disease · 2021
- [Cetuximab].Gan to kagaku ryoho. Cancer & chemotherapy · 2007
- Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis.Oncology · 2020
- Cetuximab-induced bullous pemphigoid.Italian journal of dermatology and venereology · 2023
- Cetuximab for treating non-small cell lung cancer.Expert opinion on biological therapy · 2018
via PubMed
Wikidata facts
Show 2 more facts
- World Health Organisation international non-proprietary name
- cetuximab
- Commons category
- Cetuximab
Sources (6)
via Wikidata · CC0
~7 min read
Article
16 sectionsContents
- Medical uses
- Head and neck cancer
- Colorectal cancer
- Side effects
- Alpha-gal allergy
- Mechanism of action
- KRAS Testing
- History
- Society and culture
- Manufacture
- Distribution
- Economics
- Biosimilars
- Insider trading
- Research
- References
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion.
Cetuximab was approved for medical use in the United States in 2004.
Connections
intravenous infusion and defusion
Entity
metformin
Entity
monoclonal antibody
Entity
Merck KGaA
Entity
tirzepatide
Entity
tadalafil
Entity
epidermal growth factor receptor
Protein
baricitinib
Entity
Insulin Lispro
Entity
abemaciclib
Entity
fusion protein
Entity
ramucirumab
Entity
glucagon
Entity
dinutuximab
Entity
VEGF receptors
Entity
MET proto-oncogene, receptor tyrosine kinase
Protein
necitumumab
Entity
selpercatinib
Entity
pirtobrutinib
Entity
human
Entity
Categories
Chemicals that do not have a ChemSpider ID assignedDrugboxes which contain changes to verified fieldsDrugs developed by Bristol Myers SquibbDrugs developed by Eli Lilly and CompanyDrugs developed by MerckDrugs that are a monoclonal antibodyDrugs with non-standard legal statusMonoclonal antibodies for tumors